Fig. 4From: Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trialsAssociation between trough plasma ozoralizumab concentration and ACR20 or ACR50 response in the OHZORA trial (A) and the NATSUZORA trial (B) using receiver operating characteristic analysis. ACR20/50 ≥ 20%/50% improvement according to the American College of Rheumatology criteriaBack to article page